Article
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
The New England journal of medicine - 30 Jun 2011
Chapman Paul B, Hauschild Axel, Robert Caroline, Haanen John B, Ascierto Paolo, Larkin James, Dummer Reinhard, Garbe Claus, Testori Alessandro, Maio Michele, Hogg David, Lorigan Paul, Lebbe Celeste, Jouary Thomas, Schadendorf Dirk, Ribas Antoni, O'Day Steven J, Sosman Jeffrey A, Kirkwood John M, Eggermont Alexander M M, Dreno Brigitte, Nolop Keith, Li Jiang, Nelson Betty, Hou Jeannie, Lee Richard J, Flaherty Keith T, McArthur Grant A
Abstract excerpt
BACKGROUND: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS: We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Patients were randomly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.